Twitter | Search | |
Frank Vinluan
Business journalist in Research Triangle Park on 's biotech team covering pharma, medtech, agtech. 71% free throw shooter. Genesis: Album 9, track 11.
4,252
Tweets
592
Following
1,095
Followers
Tweets
Frank Vinluan Aug 21
, can you help her out?
Reply Retweet Like
Frank Vinluan Aug 21
. is engineering viruses into targeted therapies carrying payloads of anticancer proteins. The aims to start its first human test in solid tumors in early 2020.
Reply Retweet Like
Frank Vinluan Aug 20
In $7.6B cash & stock deal for Bayer's animal health biz, sees opportunities to sell more pet products, boost its global reach. Acquisition expected to close in mid 2020
Reply Retweet Like
Frank Vinluan Aug 20
It's a CRL for . has more on the FDA's rejection of Sarepta Therapeutics' second Duchenne drug.
Reply Retweet Like
Frank Vinluan Aug 19
ICYMI late Friday, 2 more clinical-stage companies joined the queue. SpringWorks Therapeutics focuses on and rare diseases, Satsuma Pharmaceuticals on acute
Reply Retweet Like
Frank Vinluan retweeted
Reuters Top News Aug 18
Novartis executive sold shares before drug data manipulation made public
Reply Retweet Like
Frank Vinluan Aug 17
Replying to @frankvinluan
Satsuma aims to treat acute with a single-use drug/device combo product. It doses a dry powder formulation of an old, generic drug inhaled through the nose. Preliminary $86M target set; the cash would finance Ph 3 testing. S-1 here:
Reply Retweet Like
Frank Vinluan Aug 17
Replying to @frankvinluan
SpringWorks set a preliminary $115M target; the cash will support ongoing Ph 3 study tests of lead drug in desmoid tumors. Here's the S-1:
Reply Retweet Like
Frank Vinluan Aug 17
Replying to @frankvinluan
SpringWorks spun out of Pfizer 2 yrs ago with $103M in funding and 4 compounds licensed from . Here's how we covered the company's launch:
Reply Retweet Like
Frank Vinluan Aug 17
The window is still open. SpringWorks Therapeutics and Satsuma Pharmaceuticals filed paperwork after the Friday market close
Reply Retweet Like
Frank Vinluan retweeted
Ben Fidler Aug 15
Updated w/ approval of Rozlytrek --> Four New Drugs are Around the Corner. Here’s What You Need to Know.
Reply Retweet Like
Frank Vinluan Aug 15
Proteins in plant-based meat and milk have to come from somewhere. aims to be the source. The has raised $27.5M in financing to build its product pipeline
Reply Retweet Like
Frank Vinluan Aug 8
therapy has yet to reach its potential treating disease. is acquiring , betting its tech can address neuro disorders, heart failure & more. Clinical trial in is planned to start this year
Reply Retweet Like
Frank Vinluan Aug 7
After releasing preliminary Phase 3 data for its lead drug Wednesday, shares closed up nearly 15%. Here's why:
Reply Retweet Like
Frank Vinluan retweeted
Ben Fidler Aug 6
FDA: Despite “Manipulated” Data, $2M Gene Therapy Should Stay on Market
Reply Retweet Like
Frank Vinluan Aug 6
raises $89M in Series C financing as it works to bring its gene-edited seeds to the market. Target crops are corn, soybean, wheat & tomatoes
Reply Retweet Like
Frank Vinluan Aug 1
. is paying $60M to acquire Prevtec Microbia, whose compete against one of its top-selling swine health products. Here's why
Reply Retweet Like
Frank Vinluan Aug 1
In news, Amicus Therapeutics reports encouraging early clinical trial results for its experimental treatment.
Reply Retweet Like
Frank Vinluan Jul 31
Replying to @frankvinluan
And here's the plan itself:
Reply Retweet Like
Frank Vinluan Jul 31
Replying to @frankvinluan
Here's the announcement of the plan:
Reply Retweet Like